Opko Health shows an extremely favorable risk/reward asymmetry ahead of an upcoming earnings catalyst, but cash burn, a steep revenue decline, and heavy options hedging keep quality deeply below the engine's floor.
Thesis pillars
- Elevated Options Hedging→Stable
- High Asymmetry Catalyst Edge→Stable
- Quality Floor Breach→Stable
- +2 more pillars — see the Why tab for full reasoning
Opko Health, Inc. (OPK) Stock Analysis
Catalyst-Driven edge
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $1.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 14.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.00; Below-average business quality; Negative price momentum.
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody... Read more
Sell if holding. Engine safety override at $1.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 14.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.00; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.3/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 25d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-07-07Recent Developments — Opko Health, Inc.
Latest news
- NEWS 12 Health Care Stocks Moving In Thursday's After-Market Session — benzinga Jul 2, 2026 neutral
Generated 2026-07-07T13:42:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicNew York and New Jersey10-K Item 1: 'Our clinical and women's health testing services are concentrated in New York and New Jersey.'
- HIGHcounterpartyPfizer10-K Item 1A: 'Our exclusive worldwide agreement with Pfizer is important to our business.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Revenue shrinking — -17.2% YoY. Growth thesis broken unless recovery story develops.static
Unprofitable operations — net margin -36.6%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $1.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 14.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.00; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $1.40. Score 4.3/10, moderate confidence.
Take-profit target: $3.72 (+148.0% upside). Prior stop was $1.40. Stop-loss: $1.40.
Concentration risk — Geographic: New York and New Jersey; Concentration risk — Counterparty: Pfizer; Quality below floor (1.8 < 4.0).
Opko Health, Inc. trades at a P/E of N/A (forward -4.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
10 analysts cover OPK with a consensus score of 3.9/5. Average price target: $4.
What does Opko Health, Inc. do?OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and...
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.